Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome
Top Cited Papers
Open Access
- 15 August 2006
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 108 (4), 1267-1279
- https://doi.org/10.1182/blood-2005-10-007252
Abstract
Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy with manifestations of hemolytic anemia, thrombocytopenia, and renal impairment. Genetic studies have shown that mutations in complement regulatory proteins predispose to non–Shiga toxin–associated HUS (non-Stx–HUS). We undertook genetic analysis on membrane cofactor protein (MCP), complement factor H (CFH), and factor I (IF) in 156 patients with non-Stx–HUS. Fourteen, 11, and 5 new mutational events were found in MCP, CFH, and IF, respectively. Mutation frequencies were 12.8%, 30.1%, and 4.5% for MCP, CFH, and IF, respectively. MCP mutations resulted in either reduced protein expression or impaired C3b binding capability. MCP-mutated patients had a better prognosis than CFH-mutated and nonmutated patients. In MCP-mutated patients, plasma treatment did not impact the outcome significantly: remission was achieved in around 90% of both plasma-treated and plasma-untreated acute episodes. Kidney transplantation outcome was favorable in patients with MCP mutations, whereas the outcome was poor in patients with CFH and IF mutations due to disease recurrence. This study documents that the presentation, the response to therapy, and the outcome of the disease are influenced by the genotype. Hopefully this will translate into improved management and therapy of patients and will provide the way to design tailored treatments.This publication has 52 references indexed in Scilit:
- De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndromeHuman Mutation, 2006
- Complement Factor H–Associated Atypical Hemolytic Uremic Syndrome in Monozygotic Twins: Concordant Presentation, Discordant Response to TreatmentAmerican Journal of Kidney Diseases, 2006
- Denaturing HPLC-based approach for detection of COL7A1 gene mutations causing dystrophic epidermolysis bullosaBiochemical and Biophysical Research Communications, 2005
- The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohortsJournal of Medical Genetics, 2005
- The risk of recurrence of hemolytic uremic syndrome after renal transplantation in childrenPediatric Nephrology, 2003
- Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections1Transplantation, 2003
- Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding siteJournal of Molecular Biology, 2002
- Membrane cofactor protein: Importance of N- and O-glycosylation for complement regulatory functionMolecular Immunology, 1998
- The Organization of the Human Complement Factor I Gene (IF): A Member of the Serine Protease Gene FamilyGenomics, 1994
- Identification and characterization of membrane cofactor protein (CD46) in the human kidneysEuropean Journal of Immunology, 1994